Cure My Disease

Don't miss your cure!

 Log in / Sign up

Seaweed extract may soothe inflamed guts — trial puts it to the test

NCT ID NCT07786389

Disease control Sponsor: Allama Iqbal Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial asks whether a supplement made from brown algae, called fucoidan, can improve gut health in people with mild to moderate ulcerative colitis. Participants will take fucoidan or a placebo alongside their usual medication for 12 weeks. Researchers will measure changes in gut inflammation and stool consistency to see if the supplement helps restore a healthier gut.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low molecular weight fucoidan derived from brown algae (Turbinaria ornata), taken orally as a dietary supplement alongside standard care.
What this could lead to
If it works, this could point toward a natural supplement that helps calm gut inflammation and improve digestive health in people with ulcerative colitis.
What could go wrong
This is an early-phase trial, so the supplement may not prove effective or safe. It is tested only in mild-to-moderate cases, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients aged between 18-64 years; * Active mild to moderate diagnosed cases of uc * Voluntarily agreeing to participate and providing informed consent. * Exclusion Criteria: * Other autoimmune disorders and chronic diseases. * Patient with Clotting problems. * Patients using oral/intravenous steroids, leukotriene antagonists, immunosuppressant's, systemic photo chemotherapy, immunotherapy, allergen-specific immunotherapy, or Chinese herbal medicine within one month before enrolment. * Patient unable to take the trial supplements as scheduled or cooperate in filling out the questionnaire and taking a blood test. * Patients with a history of allergy * Patients suffering from serious infection requiring hospitalization assessed by a clinician * Severe organ dysfunction (e.g., heart failure, liver failure, liver cirrhosis, or renal failure assessed by a clinician. * Pregnant women or those preparing for pregnancy, and those in lactation. * Patient with hypothyroidism. * Patients with a history of allergy to Soy. * Acute severe (fulminant) UC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colitis ulcer disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allama Iqbal Medical college

    Lahore, Punjab Province, 54590, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.